Form 13-F position report

COGNITION THERAPEUTICS INC

Reported by HighTower Advisors LLC

CGTX CUSIP 19243B102 Manager CIK 0001462245

First reported at 28,561 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q1 2023
Shares 28,561 Quarter-end amount reported
Reported value $58,000 Fair value at quarter end
Consecutive quarters held 1 Through Q1 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-03-31 58000
2023-06-30 48000
2023-09-30 47000
2023-12-31 61000
2024-03-31 41000
2024-06-30 38000
2024-09-30 11000
2024-12-31 13649
2025-03-31 10294
2025-06-30 5267
2025-09-30 33075
2025-12-31 32400
2026-03-31 18228
2026-06-30 30475

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for COGNITION THERAPEUTICS INC held by HighTower Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Added 26,500 +2,500 (10.4%) < 0.01% $30,475 2026-08-05
Q1 2026 Unchanged 24,000 0 (0.0%) < 0.01% $18,228 2026-05-05
Q4 2025 Reduced 24,000 -500 (-2.0%) < 0.01% $32,400 2026-02-06
Q3 2025 Added 24,500 +7,500 (44.1%) < 0.01% $33,075 2025-11-07
Q2 2025 Reduced 17,000 -7,462 (-30.5%) < 0.01% $5,267 2025-08-11
Q1 2025 Added 24,462 +5,000 (25.7%) < 0.01% $10,294 2025-05-13
Q4 2024 Reduced 19,462 -3,500 (-15.2%) < 0.01% $13,649 2025-02-07
Q3 2024 Unchanged 22,962 0 (0.0%) < 0.01% $11,000 2024-11-14
Q2 2024 Unchanged 22,962 0 (0.0%) < 0.01% $38,000 2024-08-13
Q1 2024 Reduced 22,962 -10,000 (-30.3%) < 0.01% $41,000 2024-05-06
Q4 2023 Unchanged 32,962 0 (0.0%) < 0.01% $61,000 2024-02-12
Q3 2023 Added 32,962 +6,401 (24.1%) < 0.01% $47,000 2023-11-08
Q2 2023 Reduced 26,561 -2,000 (-7.0%) < 0.01% $48,000 2023-08-14
Q1 2023 New 28,561 +28,561 (0.0%) < 0.01% $58,000 2023-05-12

Who else reported the position

38 managers reported COGNITION THERAPEUTICS INC for Q1 2023.

Managers reporting COGNITION THERAPEUTICS INC in Q1 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PATHSTONE FAMILY OFFICE LLC Unchanged 2,210,377 0 0.07% $4,376,546 4 qtrs
AIGH Capital Management LLC Unchanged 2,037,853 0 1.49% $4,034,949 6 qtrs
VANGUARD GROUP INC Added 643,390 +98,501 < 0.01% $1,273,912 6 qtrs
Worth Venture Partners LLC Unchanged 501,719 0 0.48% $993,404 5 qtrs
CARLSON CAPITAL L P Added 245,169 +15,269 0.05% $485,435 3 qtrs
Perigon Wealth Management LLC Reduced 225,000 -1,000 0.03% $445,500 4 qtrs
AMERICAN FINANCIAL GROUP INC Unchanged 205,000 0 0.13% $406,000 6 qtrs
COMMONWEALTH EQUITY SERVICES LLC Reduced 168,692 -20,615 < 0.01% $334,000 5 qtrs
Voss Capital LLC Reduced 159,973 -6,930 0.04% $316,747 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Unchanged 122,598 0 < 0.01% $242,744 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2023
Filed
May 12, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
28,561
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.